Sorafenib
Treatment for Thyroid Cancer
Typical Dosage: 400 mg orally twice daily
Effectiveness
60%
Safety Score
30%
Clinical Trials
20
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanideโ ๏ธ
Meth๐
Cigarettes๐ฌ
Chemoโข๏ธ
Alcohol๐บ
Morphine๐
Antibiotics๐
Tylenol๐
Exercise๐
Water๐ง
30
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg orally twice daily
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$190,000
Monitoring:$4,000
Side Effect Mgmt:$6,000
Total Annual:$200,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$300,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$1,666,667
Cost per Remission
$40,000,000
Comparison vs Lenvatinib
Cost Difference
$-10,000/year
Less expensive
QALY Difference
-0.15 QALYs
Worse outcomes
Dominance
No dominance
Sorafenib Outcomes
for Thyroid Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+12%
Remission Rate
+0.5%
Common Side Effects
Palmar-plantar erythrodysesthesia syndrome (PPE)
+76%
Diarrhea
+69%
Alopecia
+67%
Rash/desquamation
+55%
Fatigue
+51%
Hypertension
+41%
Weight loss
+37%
Sources:
Active Clinical Trials
4 active trials recruiting for Sorafenib in Thyroid Cancer
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
NCT02185560ACTIVE NOT RECRUITING
453 participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Jun 27, 2014
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
NCT01141309ACTIVE NOT RECRUITINGPHASE2
41 participants
INTERVENTIONAL
Basking Ridge, United States +3 more
Started: Jun 1, 2010
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
NCT02143726ACTIVE NOT RECRUITINGPHASE2
35 participants
INTERVENTIONAL
Jacksonville, United States +20 more
Started: Oct 9, 2014
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
NCT06482086RECRUITINGPHASE2
75 participants
INTERVENTIONAL
Chengdu, China
Started: Jun 1, 2021
Completed Clinical Trials
10 completed trials for Sorafenib in Thyroid Cancer
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
NCT02114658COMPLETEDPHASE2
18 participants
INTERVENTIONAL
Kobe, Japan +4 more
Started: Apr 15, 2014
Nexavarยฎ Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
NCT00984282COMPLETEDPHASE3
417 participants
INTERVENTIONAL
Los Angeles, United States +80 more
Started: Oct 15, 2009
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
NCT02303444COMPLETED
667 participants
OBSERVATIONAL
Birmingham, United States +33 more
Started: Apr 8, 2015
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
NCT00390325COMPLETEDPHASE2
21 participants
INTERVENTIONAL
St Louis, United States +2 more
Started: Nov 3, 2006
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
NCT00887107COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Leiden, Netherlands
Started: Oct 1, 2007
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
NCT02084732COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Bogotรก, Colombia
Started: Oct 1, 2013
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
NCT00654238COMPLETEDPHASE2
59 participants
INTERVENTIONAL
Philadelphia, United States
Started: Feb 1, 2006
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
NCT01025453COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Basking Ridge, United States +4 more
Started: Dec 1, 2009
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
NCT03565536COMPLETEDPHASE2
18 participants
INTERVENTIONAL
Fuzhou, China
Started: May 1, 2018
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
NCT01502410COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Birmingham, United States +91 more
Started: Jan 1, 2012